- Tiziana is developing Milciclib for the treatment of HCC, the worlds most common primary cancer and a leading cause of cancer-related death in the United States.
- Between 2003 to 2012, rates of new liver cancer cases went up 38% according to the Centers for Disease Control and Prevention.
- Most HCC patients present with advanced disease and do not benefit from transplantation, surgical resection, or locoregional therapies.
- Sorafenib (standard of care) and Lenvatinib are approved in the United States and EU as first line-treatment for advanced HCC patients.
- The primary risk factor for HCC is hepatic cirrhosis.
The following graphic represents the progression from a healthy liver to NAFLD, NASH, cirrhosis and HCC.